drugset / Trial / NCT05139030
Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of the study is to compare magnitude of postsurgical analgesic effect in different groups following a single dose of study drug when administered via adductor canal block in subjects undergoing primary unilateral total knee arthroplasty.
Timeline
- Start
- 2022-01-18
- Primary completion
- 2022-07-11
- Completion
- 2022-07-11
Publications
- Gadsden J, Gonzales J, Saha P. Plain language summary of a pain medication (liposomal bupivacaine) for pain relief after knee replacement surgery. Pain Manag. 2026 Feb;16(2):77-86. doi: 10.1080/17581869.2025.2592701. Epub 2025 Dec 19.
- Gadsden J, Hamilton M, Schwartz G, Gonzales J, Hutchins J, Saha P, Song J, DiGiorgi M, Winston R. A Phase 3 Active-Controlled Trial of Liposomal Bupivacaine via Adductor Canal Block for Total Knee Arthroplasty. J Arthroplasty. 2025 Oct;40(10):2605-2614.e5. doi: 10.1016/j.arth.2025.07.030. Epub 2025 Jul 22.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bupivacaine | Other / unclassified | 50 mg | Other |
| Comparator | Bupivacaine | Other / unclassified | 133 mg | Other |